Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Next Previous
Search
Trial Profile

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deuruxolitinib (Primary)
  • Indications Alopecia areata
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Concert Pharmaceuticals

    • Most Recent Events

    • 07 Jun 2022 Results published in the Concert Pharmaceuticals Media Release.
    • 29 Mar 2022 Results published in the Journal of the American Academy of Dermatology
    • 08 Jul 2020 According to a Concert Pharmaceuticals media release, the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the CTP-543 for the treatment of adult patients with moderate-to-severe alopecia areata.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top